

Fan Xing Xing



Position Assistant Professor

Faculty State Key Laboratory of Quality
Research in Chinese Medicines

Email address xxfan@must.edu.mo

Office H836

**Mailing
address** Room 836, Block H, Macau
University of Science and
Technology, Avenida Wai Long,
Taipa, Macau

Teaching and Research Areas

Molecular pharmacology, Cancer immunotherapy

Academic Qualifications

2011-2014 PhD/Chinese Medicines/Macau University of Science and
Technology

2007-2010 MPhil / Pathogen biology / TianJin Medical University

2002-2007 BSC / Clinical Medicine / TianJin Medical University

Experiences

2014-2017 Postdoctoral training/ SKL of quality research in Chinese
Medicines / Macau University of Science and Technology

Representative Publications

Journal Articles: (*corresponding author(s); #contribution equally)

1. **Fan XX[#]**, Pan HD[#], Li Y, Guo RJ, Leung EL^{*}, Liu L^{*}. Novel therapeutic strategy for cancer and autoimmune conditions: Modulating cell metabolism and redox capacity. *Pharmacol Ther.* 2018 Jun 25. pii: S0163-7258(18)30112-8.

2. Li RZ[#], **Fan XX[#]**, Duan FG, Jiang ZB, Pan HD1, Luo LX, Zhou YL, Li Y, Yao YJ,

Yao XJ, Leung EL^{*}, Liu L^{*} ET EMC /P A CID 23/Lang/P TJ12 123a/F2 12 Tf1 0 0 1 316.85 749.52

survival in lung adenocarcinoma. *Oncotarget*. 2016 Jun 28; 7 (26): 39970-39979.

9. Wang MF, Li RZ, Li Y, Cheng XQ, Yang J, Chen W, **Fan XX**, Pan HD, Yao XJ, Ren T, Qian X, Liu L, Leung EL*, Tang YJ*. Clinical statistics analysis on the characteristics of pneumoconiosis of Chinese miner population. *J Thorac Dis*. 2016 Aug;8(8):2203-11.

10. Jiang JB[#], Huang J[#], Xie C, Li X, Liu L, He J, Pan H, Huang L, **Fan XX**, Yao XJ, Xie Y, Li N, Liu L, He JX* & Leung EL*. Combined use of PI3k and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutation. *Oncology Reports*. 2016 Jul; 36(1):365-75.

11. Xu SW, Law BY, Mok SW, Leung EL, **Fan XX**, Coghi PS, Zeng W, Leung CH, Ma DL, Liu L, Wong VK*. Autophagic degradation of epidermal growth factor receptor in gefitinib-resistant lung cancer by celastrol. *Int J Oncol*. 2016 Oct; 49(4):1576-88.

12. Zhang YZ[#], Chen X[#], **Fan XX**, He JX, Huang J, Xiao DK, Zhou YL, Zheng SY, Xu JH, Yao XJ, Liu L* & Leung EL*. Compound library screening identified cardiac glycoside digitoxin as effective growth inhibitor of gefitinib-resistant non-small cell lung cancer via downregulation of α -tubulin and inhibition of microtubule formation. *Molecules*. 2016 Mar 18; 21(3).

13. **Fan XX**, Yao XJ, Xu SW, Wong VKW, He JX, Ding J, Xue WW, Mujtaba T, Michelangeli F, Huang M, Huang J, Xiao DK, Jiang ZB, Zhou YL, Kam R.K., Liu L*, Leung EL* -Trans-tetramethoxystilbene, a new analogue of resveratrol, inhibits gefitinib-resistant non-small cell lung cancer via selectively elevating intracellular calcium level. *Sci Reports*. 2015 Nov 6; 5:16348.

14. Leung EL, **Fan XX**, Wong MP, Jiang ZH, Liu ZQ, Yao XJ, Lu LL, Zhou YL, Yau LF, Tin PC, Liu L*. Targeting tyrosine kinase inhibitor resistant non-small-cell lung cancer by inducing EGFR degradation via methionine 790 oxidation. *Antioxid Redox Signal*. 2016 Feb 10;24(5):263-79.

15. Yuan ZW, Leung EL, **Fan XX**, Ma WZ, Liu L, Xie Y*. Quantitative evaluation of berberine subcellular distribution and cellular accumulation in non-small cell lung cancer cells by UPLC-MS/MS. *Talanta*. 2015 Nov 1; 144: 20-8.

16. **Fan XX**, Li N, Wu JL, Zhou YL, He JX, Liu L and Leung EL*. Celastrol Induces Apoptosis in Gefitinib-Resistant Non-Small Cell Lung Cancer Cells via Caspases-Dependent Pathways and Hsp90 Client Protein Degradation. *Molecules*. 2014 Mar 21; 19(3):3508-22.